DDR1 and neoplasm: Enrichment analysis of the DDR1-high and DDR1-low groups revealed enrichment of the cell cycle and PI3K–Akt signaling pathways, both of which are well-established drivers of tumor proliferation, survival, and therapeutic resistance in NSCLC (84, 85).